The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SONN | -40.49% | -99.95% | -78% | -100% |
| S&P | +14.5% | +93.32% | +14.09% | +165% |
Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded in 2011 and is headquartered in Princeton, NJ.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.02M | -5.3% |
| Gross Margin | 97.78% | 105.0% |
| Market Cap | $3.93M | 34.5% |
| Market Cap / Employee | $0.30M | 0.0% |
| Employees | 13 | 0.0% |
| Net Income | -$3.78M | -7.7% |
| EBITDA | -$3.78M | -7.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.32M | -91.0% |
| Accounts Receivable | $0.50M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $0.07M | -15.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -345.29% | -244.4% |
| Return On Invested Capital | 4382.37% | 368.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.76M | 42.7% |
| Operating Free Cash Flow | -$1.76M | 42.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -8.96 | -1.95 | 1.00 | 5.85 | 512.18% |
| Price to Sales | 233.57 | 2.95 | 5.25 | 4.92 | -94.18% |
| Price to Tangible Book Value | 1.67 | -1.95 | 1.00 | 5.85 | 512.18% |
| Enterprise Value to EBITDA | -1.37 | 0.64 | -0.78 | -1.23 | 227.90% |
| Return on Equity | -200.1% | -264.6% | -285.3% | -715.0% | - |
| Total Debt | $0.13M | $0.11M | $0.09M | $0.07M | -54.17% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
